There was no significant difference in overall survival between groups ( median overall survival 128 months [ 955 % CI 105-143 ] in the doxorubicin group vs 143 months [ 125-165 ] in the doxorubicin and ifosfamide group ; hazard ratio [ HR ] 083 [ 955 % CI 067-103 ] ; stratified log-rank test p = 0076 ) .